Patents Examined by Kamal Saeed
  • Deuterated Alpha5 subunit-selective negative allosteric modulators of gamma-aminobutyric acid type A receptors as fast acting treatment for depression and mood disorders
    Patent number: 11459320
    Abstract: The present invention relates to novel alpha5 subunit-selective negative allosteric modulators of GABAA receptors that have been deuterated to improve their medicinal properties by prolonging their half-lives, rendering them useful as fast-acting pharmaceutical treatments for depression related disorders.
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: October 4, 2022
    Assignees: UNIVERSITY OF MARYLAND, BALTIMORE, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Scott Thompson, Adam Van Dyke, Craig Thomas, Patrick Morris
  • Therapeutic compounds and methods to treat infection
    Patent number: 11458121
    Abstract: Disclosed herein are compounds of formula I: or a salt thereof and compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods for treating or preventing a bacterial infection in an animal comprising administering to the animal a compound of formula I or a pharmaceutically acceptable salt thereof, alone or in combination with a bacterial efflux pump inhibitor.
    Type: Grant
    Filed: June 26, 2018
    Date of Patent: October 4, 2022
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Edmond J. LaVoie, Ajit Parhi, Hye Yeon Sagong
  • Diabetes and metabolic syndrome treatment with a novel dual modulator of soluble epoxide hydrolase and peroxisome proliferator-activated receptors
    Patent number: 11447445
    Abstract: N-benzylbenzamides that act as dual soluble epoxide hydrolase (sEH)/peroxisome proliferator-activated receptor ? (PPAR?) modulators and are useful as medications in the treatment of Metabolic Syndrome (MetS) cluster diseases, including diabetes. Methods of making and using the same are further provided.
    Type: Grant
    Filed: December 23, 2020
    Date of Patent: September 20, 2022
    Assignees: The Medical College of Wisconsin, Inc., Johann Wolfgang Goethe-Universität Frankfurt
    Inventors: John David Imig, Md. Abdul Hye Khan, Eugen Proschak, Rene Blocher
  • Biheterocyclic compound
    Patent number: 11440905
    Abstract: The present invention provides a compound of formula (1) and a pharmaceutical composition comprising the compound useful as a nerve regeneration promoter wherein R1-L- is R1—OC(O)—, or the like, R1 is hydrogen atom, optionally-substituted C1-6 alkyl group, optionally-substituted 3- to 8-membered cycloalkyl group, or the like, R2 is hydrogen atom or the like, Ring A is formula (2) or formula (3) wherein R3 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like, the part of X, Y, and Z is X?Y—Z, X—Y?Z, or X—Y—Z, X is nitrogen atom, NR4 (R4 is hydrogen atom, optionally-substituted C1-6 alkyl group, or the like), or the like, Y is carbon atom or the like, and Z is carbon atom, nitrogen atom or the like.
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: September 13, 2022
    Assignee: SUMITOMO PHARMA CO., LTD.
    Inventors: Hitoshi Watanabe, Yoshiaki Isobe, Hidenori Kimura, Yuji Fujiwara
  • Beta-lactam compounds or salts thereof for use in long-acting prevention or treatment of a glucose metabolism disorder
    Patent number: 11419852
    Abstract: Provided is a long-acting method for preventing or treating glucose metabolism disorders that includes administering a beta-lactam compound or a pharmaceutically acceptable salt thereof to a subject in need thereof. The method for preventing or treating glucose metabolism disorders has a long-acting effect that lasts more than two days even after medication has been stopped.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: August 23, 2022
    Assignee: GLYCOLYSIS BIOMED CO., LTD.
    Inventors: Feng-Ling Lee, Lung-Jr Lin, Jyh-Shing Hsu, Cheng-Hsien Hsu, Yen-Chun Huang, Ya-Chien Huang, Chun-Tsung Lo, Hui-Fang Liao, Yu-Wen Liu, Yu-Chi Kao
  • Process for the synthesis of lactams
    Patent number: 11401240
    Abstract: A process for the synthesis of lactams suitable for use in antimicrobial, anti-biofilm and bacteriostatic compositions.
    Type: Grant
    Filed: October 23, 2019
    Date of Patent: August 2, 2022
    Assignee: Conopco, Inc.
    Inventors: David Anthony Dawkins, Panagiotis Kotsakis, Neil James Parry, David William Thornthwaite
  • Crystalline polymorphic forms of monosodium n-[-8-(2-hydroxybenzoyl)amino]caprylate
    Patent number: 11395809
    Abstract: The present invention relates to crystalline polymorphic forms of monosodium N-[8-(2-hydroxybenzoyl)amino] caprylate (“SNAC”), including two hydrates, a methanol solvate, and an ethanol solvate, of SNAC. More specifically, the present invention provide six polymorphic forms of SNAC (hereafter referred to as Forms I-V). The present invention also provides an amorphous form of SNAC.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: July 26, 2022
    Assignee: NOVO NORDISK NORTH AMERICA OPERATIONS A/S
    Inventors: Halina Levchik, Shingai Majuru, Brahma Singh, Jamila Harris
  • Crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenox
    Patent number: 11390615
    Abstract: The present invention relates to a crystalline form of the compound (S)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol.
    Type: Grant
    Filed: October 14, 2020
    Date of Patent: July 19, 2022
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Cyrille Lescop, Jasper Dingemanse, Andreas Krause
  • Pesticidally active cyclopropyl methyl amide derivatives
    Patent number: 11388902
    Abstract: The present invention relates to compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts, stereoisomers, enantiomers, tautomers and N-oxides of those compounds; to intermediates for preparing compounds of formula (I), to compositions comprising them and to methods of using them to combat and control insect, acarine, nematode and mollusc pests.
    Type: Grant
    Filed: March 22, 2018
    Date of Patent: July 19, 2022
    Assignee: SYNGENTA PARTICIPATIONS AG
    Inventors: Jérôme Yves Cassayre, Myriem El Qacemi, Thomas Pitterna, André Stoller
  • Use of carbamate compound for preventing, alleviating or treating myotonia
    Patent number: 11389429
    Abstract: The present invention relates to a use of a carbamate compound represented by chemical formula 1, or a pharmaceutically acceptable salt, a solvate or a hydrate thereof for preventing, alleviating or treating myotonia.
    Type: Grant
    Filed: November 13, 2018
    Date of Patent: July 19, 2022
    Assignee: SK BIOPHARMACEUTICALS CO., LTD.
    Inventors: Hye Won Shin, Ji Hye Kim
  • Process for preparation of Siponimod, its salts and solid state forms thereof
    Patent number: 11390583
    Abstract: The present application provides process for preparation of siponimod, intermediates of siponimod, salts of siponimod, polymorphic forms and solid dispersions of siponimod and its salts thereof. The present application specifically provides crystalline polymorphic forms of siponimod base, siponimod hemifumarate and other salts and pharmaceutical compositions thereof. Also provided are solid dispersions of siponimod hemifumarate and pharmaceutical compositions containing them.
    Type: Grant
    Filed: September 26, 2018
    Date of Patent: July 19, 2022
    Assignee: DR. REDDY'S LABORATORIES LIMITED
    Inventors: Srinivas Oruganti, Krishnarao Chintada, Bhaskar Kandagatla, Raju Cheerlavancha, Vamsi Krishna Mudapaka, Rajasekhar Voguri, Rajesh Thipparaboina, Satyanarayana Thirunahari
  • Compounds for targeting mutant huntingtin protein and uses thereof
    Patent number: 11389438
    Abstract: The present disclosure relates generally to compounds that simultaneously bind both mutant huntingtin protein (mHTT) and an ubiquitin E3 ligase and their use as therapeutic agents, for example, in treating diseases, such as neurodegenerative disorders caused by aggregation of mHTT.
    Type: Grant
    Filed: February 24, 2020
    Date of Patent: July 19, 2022
    Assignee: CHDI Foundation, Inc.
    Inventors: Celia Dominguez, Jonathan Bard, Matthew R. Lee, Longbin Liu, Michael Edward Prime, Samuel Coe
  • BAX activators and uses thereof in cancer therapy
    Patent number: 11382898
    Abstract: Activators of BAX and their uses in cancer therapy are disclosed.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: July 12, 2022
    Assignee: Albert Einstein College of Medicine
    Inventors: Evripidis Gavathiotis, Denis E. Reyna, Felix Kopp, Ulrich G. Steidl
  • Processes for preparing oligomers
    Patent number: 11384105
    Abstract: Provided herein are processes for preparing an oligomer (e.g., a morpholino oligomer). The synthetic processes described herein may be advantageous to scaling up oligomer synthesis while maintaining overall yield and purity of a synthesized oligomer.
    Type: Grant
    Filed: November 16, 2020
    Date of Patent: July 12, 2022
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Baozhong Cai, Mitchell Martini, Ross Shimabuku, Katie Thomas, Diane Elizabeth Frank, Richard K. Bestwick
  • Small molecule modulators of IL-17
    Patent number: 11377425
    Abstract: The present invention relates to a compound according to formula I and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: July 5, 2022
    Assignee: Leo Pharma A/S
    Inventors: Kevin Neil Dack, Xifu Liang, Mogens Larsen, Mark Andrews, Alan Stuart Jessiman, Mia Nørreskov Burhardt, Patrick Stephen Johnson, Peter Andersen, Lars Jørgensen
  • Cyclooctynes for click chemistry
    Patent number: 11377424
    Abstract: Provided herein are dibenzocyclooctyne compounds useful as reagents in 1,3-dipolar cycloaddition reactions, and methods for their preparation.
    Type: Grant
    Filed: May 27, 2021
    Date of Patent: July 5, 2022
    Assignee: MASSACHUSETTS INSTITUTE OF TECHNOLOGY
    Inventors: Ronald T. Raines, Brian Gold, Jesús M. Dones, Nile S. Abularrage, Brian James Graham
  • Solid forms of (E)-3-[2-(2-thienyl)vinyl]-1H-pyrazole
    Patent number: 11370783
    Abstract: The present disclosure provides solid forms of (E)-3-[2-(2-thienyl)vinyl]-1H-pyrazole, compositions thereof, and methods of making and using the same.
    Type: Grant
    Filed: December 1, 2020
    Date of Patent: June 28, 2022
    Assignee: Angion Biomedica Corp.
    Inventors: An-Hu Li, Satish Kumar Sakilam, Dong Sung Lim
  • Modulator of indoleamine 2,3-dioxygenase, preparation method and use thereof
    Patent number: 11369589
    Abstract: The present invention relates to a modulator of 1,2,5-oxadiazole indoleamine-(2,3)-dioxygenase, a preparation method and use thereof, more particularly to compounds of Formula I and Formula II, an isomer thereof, a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof, and their use in preparing drugs for treating cancers, neurodegenerative diseases, eye diseases, mental disorders, depression, anxiety disorders, Alzheimer's diseases and/or autoimmune diseases. Specific meanings of R substituents in Formula I and Formula II are consistent with the description of the specification.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: June 28, 2022
    Assignees: NANJING CAREPHAR SHENGHUI PHARMACEUTICAL CO., LTD., JIANGSU CAREPHAR PHARMACEUTICAL CO., LTD.
    Inventors: Yinlin Qin, Mei Su, Min Ji, Haidong Liu, Xi Zong, Xianzhi Wu
  • Compounds and methods for regulating, limiting, or inhibiting expression
    Patent number: 11369608
    Abstract: In one aspect, the disclosure relates to compounds useful to regulate, limit, or inhibit the expression of AVIL (advillin), methods of making same, pharmaceutical compositions comprising same, and methods of treating disorders associated with AVIL dys-regulation using same. In aspects, the disclosed compounds, compositions and methods are useful for treating disorders or diseases in which the regulation, limitation, or inhibition of the expression of AVIL can be clinically useful, such as, for example, the treatment of cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: June 28, 2022
    Assignee: University of Virginia Patent Foundation
    Inventors: Hui Li, Zhongqiu Xie
  • Sulcardine administration for treatment of acute atrial fibrillation
    Patent number: 11364223
    Abstract: Provided herein are compositions and methods for administration of sulcardine to a subject in need thereof.
    Type: Grant
    Filed: December 12, 2019
    Date of Patent: June 21, 2022
    Assignee: HUYABIO International, LLC
    Inventors: Suzanne J. Romano, Gary T. Elliott